SEC Filing Summary: Genesis Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on July 22, 2011, reporting events occurring on July 20, 2011. The company is incorporated in Nevada and headquartered in Los Angeles, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of General Merrill A. McPeak to the Company's Board of Directors, effective July 20, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. It serves solely to disclose the board appointment.
Key Facts for Investor Verification
- Verify the background and qualifications of the newly appointed director, General Merrill A. McPeak.
- Confirm the company name is Genesis Biopharma, Inc., as the input metadata referenced IOVANCE Biotherapeutics, Inc.
- Note that no financial performance data is included in this specific filing.